Bolt Biotherapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Bolt Biotherapeutics generated cash of -$69,525,000, which is more than the previous year. Cash used in financing activities reached the amount of $253,000 last year. Net change in cash is therefore $1,766,000.
Cash Flow
| 2018 | -9.87M | -290K | 19.09M |
|---|---|---|---|
| 2019 | -26.34M | -508K | 48.62M |
| 2020 | -47.30M | -20.59M | 39.59M |
| 2021 | -57.06M | -232.20M | 311.10M |
| 2022 | -76.50M | 57.86M | 503K |
| 2023 | -69.52M | 71.03M | 253K |
BOLT Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 10.80M | 28.94M | 7.10M | 35.41M | 13.63M | 4.70M |
Operating activities | ||||||
Net income | -69.19M | -88.09M | -98.59M | -60.72M | -30.48M | -11.58M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 1.85M | 1.66M | 1.19M | 611K | 335K | 302K |
Stock-based compensation expense | 9.22M | 9.57M | 8.5M | 1.42M | 508K | 0 |
| Deferred income tax benefit | 9.22M | 9.57M | 8.5M | 1.42M | 508K | 0 |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -3.41M | 2.76M | 6.67M | 2.88M | 0 | 0 |
Cash generated by operating activities | -69.52M | -76.50M | -57.06M | -47.30M | -26.34M | -9.87M |
Investing activities | ||||||
Purchases Of Investments | -164.98M | -180.70M | -313.37M | -33.22M | 0 | 0 |
Investments In Property Plant And Equipment | -206K | -1.95M | -2.33M | -3.26M | -508K | -290K |
Acquisitions Net | 0 | -59.81M | 229.86M | 17.33M | 0 | 0 |
Cash generated by investing activities | 71.03M | 57.86M | -232.20M | -20.59M | -508K | -290K |
Financing activities | ||||||
Common Stock Issued | 253K | 503K | 311.10M | 294K | 72K | 20K |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | -40K | -39K |
Cash used in financing activities | 253K | 503K | 311.10M | 39.59M | 48.62M | 19.09M |
Net Change In Cash | 1.76M | -18.13M | 21.84M | -28.30M | 21.77M | 8.93M |
Cash at end of period | 12.57M | 10.80M | 28.94M | 7.10M | 35.41M | 13.63M |
| Data source | Data source | Data source | Data source |